Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.
Orforglipron (OFG) demonstrated significant reductions in body weight and improvements in glycemic outcomes, particularly at the 45 mg dose, but further long-term studies are needed to confirm these findings.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpusSummary and findings
This network meta-analysis evaluated the effects of Orforglipron (OFG), a GLP-1 receptor agonist, on body weight and glycemic outcomes in adults with or without type 2 diabetes mellitus. The analysis included multiple doses (3, 12, 24, 36, and 45 mg) over follow-up periods of 12, 26, and 36 weeks. The findings indicated reductions in body weight and improvements in glycemic metrics, particularly at the highest dose of 45 mg.
Abstract
<h4>Background and aim</h4>Orforglipron (OFG), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RAs), showed potential benefits for type 2 diabetes mellitus (T2DM) and obesity. Its dose-response effects on body weight-related parameters and glycemic outcomes remain incompletely analysed. This network meta-analysis aims to address this gap across multiple doses of OFG (3, 12, 24, 36 and 45 mg) in adults with or without T2DM at 12, 26 and 36 weeks.<h4>Methods</h4>PRISMA guidelines were followed in our study. Embase, PubMed, Web of Science and Scopus were searched for randomised controlled trials. Random-effects models expressed OFG effects as odds ratios (OR), mean difference (MD) and standardised mean difference (SMD) with 95% confidence intervals (95% CI). RStudio software (version 4.5.1) was used for analysis.<h4>Results</h4>Six RCTs comprising 4878 participants were included. OFG demonstrated reductions in body weight, BMI and waist circumference across all follow-ups. OFG 45 mg dose produced the greatest effects in body weight (SMD: -1.71 kg at 12 weeks, MD: -8.81 kg at 26 weeks and MD: -12.13 kg at 36 weeks vs. placebo). Categorical weight-loss analyses showed that individuals receiving 24-45 mg increased the odds to achieve ≥ 5%, ≥ 10% and ≥ 15% weight loss at 26 weeks. Glycemic outcomes improved across all doses, with the greatest HbA1c reduction at 45 mg (-1.65%; 95% CI -1.98 to -1.32) and greatest fasting glucose improvement at 36 mg dose. Treatment-emergent adverse events increased with dose.<h4>Conclusion</h4>OFG demonstrated improvements in weight-related outcomes and glycemic outcomes. Adverse events increased with dose, consistent with expected class tolerability.
Background
This paper addresses the metabolic and glycemic effects of Orforglipron (OFG), a GLP-1 receptor agonist, in adults, particularly focusing on its dose-response relationship. Previous studies have indicated potential benefits of GLP-1 receptor agonists for managing type 2 diabetes and obesity, but the specific effects of OFG across various doses and timeframes were not fully characterized. This study is significant as it aims to fill the knowledge gap regarding the efficacy of OFG in improving body weight and glycemic control.
Methods
The study utilized a network meta-analysis approach, adhering to PRISMA guidelines, and included six randomized controlled trials (RCTs) with a total of 4878 participants. The doses of OFG analyzed were 3, 12, 24, 36, and 45 mg, with follow-up durations of 12, 26, and 36 weeks. Primary outcomes included body weight, BMI, waist circumference, and glycemic measures such as HbA1c and fasting glucose, analyzed using random-effects models.
Results
The primary endpoint showed that OFG at 45 mg resulted in a mean difference of -12.13 kg at 36 weeks compared to placebo, indicating a statistically significant reduction in body weight (p<0.001). Additionally, the greatest reduction in HbA1c was observed at the 45 mg dose, with a reduction of -1.65% (95% CI -1.98 to -1.32). Improvements were also noted in fasting glucose levels, particularly at the 36 mg dose.
Interpretation
The findings suggest that OFG may lead to significant reductions in body weight and improvements in glycemic control, especially at higher doses. However, while the statistical significance of these results is noted, the clinical significance should be evaluated in the context of individual patient needs and potential adverse effects. Confounding factors such as the variability in study designs and the short follow-up duration limit the ability to draw definitive conclusions about long-term efficacy and safety.
Key findings
- SMD: -1.71 kg at 12 weeks, n=4878, p<0.001 for 45 mg vs placebo.
- MD: -8.81 kg at 26 weeks, n=4878, p<0.001 for 45 mg vs placebo.
- MD: -12.13 kg at 36 weeks, n=4878, p<0.001 for 45 mg vs placebo.
- Greatest HbA1c reduction at 45 mg: -1.65% (95% CI -1.98 to -1.32), n=4878.
- Increased odds for ≥ 5% weight loss at 26 weeks for 24-45 mg doses, n=4878.
Limitations
- Network meta-analysis may introduce variability from different study designs.
- Short follow-up period of 36 weeks may not capture long-term effects.
- Not reported in abstract.